|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
|
22193042 |
2012 |
|
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We found that high-grade serous ovarian carcinoma had significantly higher MIR182 (P=0.0003) and HMGA2 (P=0.04) expression, and significantly lower BRCA1 (P<0.0001) and FOXO3 (P<0.001) expression than normal controls.
|
22790015 |
2012 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
With the recent introduction of Poly(ADP-ribose) polymerase inhibitors, a promising novel therapy has become available for ovarian carcinoma (OC) patients with inactivating BRCA1 or BRCA2 mutations in their tumor.
|
27767231 |
2017 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Increased cell survival by inhibition of BRCA1 using an antisense approach in an estrogen responsive ovarian carcinoma cell line.
|
11056686 |
2000 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the BRCA1 and BRCA2 genes are associated with an inherited predisposition to breast and ovarian carcinoma, and specific mutations in these genes are found at increased frequency in certain populations.
|
12879478 |
2003 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study suggests that BRCA1 protein is a prognostic marker in sporadic OC patients with minimal RD.
|
21368065 |
2011 |
|
Ovarian Carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
|
24385383 |
2014 |
|
Ovarian Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Low BRCA1 expression in primary sporadic ovarian carcinoma is associated with prolonged survival.
|
19602291 |
2009 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience.
|
29460478 |
2018 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
|
29233532 |
2018 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Women with family histories suggestive of an increased risk of ovarian carcinoma who have not had a deleterious BRCA1 or BRCA2 mutation identified are commonly suggested to consider ovarian carcinoma screening with transvaginal ultrasound and/or assessment of CA 125 levels.
|
15948173 |
2005 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In women with breast cancer, mutations in BRCA1 and BRCA2 were associated with a 10-fold increased risk of subsequent ovarian carcinoma (P = .005).
|
9667259 |
1998 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Transitional cell ovarian carcinoma is a rare histologic variant of epithelial ovarian cancer that may occur in BRCA1 mutation carriers.
|
11975969 |
2002 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
|
19060844 |
2009 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
|
30266954 |
2018 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Four carriers of pathogenic mutations in both BRCA1 and BRCA2 were identified among women who underwent genetic counseling for hereditary susceptibility to breast and ovarian carcinoma at three different Italian institutions.
|
20373018 |
2010 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRCA1 is a tumor suppressor gene that is responsible for hereditary breast and ovarian carcinoma syndrome.
|
11443609 |
2001 |
|
Ovarian Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings confirm a high rate of loss of BRCA1 protein expression in sporadic OEC and suggest a role of BRCA1 in the progression of sporadic ovarian carcinoma.
|
16515585 |
2006 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A patient with breast carcinoma diagnosed at the age of 30 years and ovarian carcinoma diagnosed at the age of 41 years was found to have germline mutations in both the BRCA1 and the BRCA2 genes.
|
9790802 |
1998 |
|
Ovarian Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The germline BRCA1 mutation rate in USC subjects of 2% is higher than expected in a nonfounder population, suggesting that USC is associated with hereditary breast and ovarian carcinoma in a small proportion of cases.
|
22811390 |
2013 |